2OVM

Progesterone Receptor with Bound Asoprisnil and a Peptide from the Co-Repressor NCoR

Summary for 2OVM

• Entry DOI: 10.2210/pdb2ovm/pdb
• Related: 1A28 2OVH
• Descriptor: Progesterone receptor, NCoR, 4-[(11BETA,17BETA)-17-METHOXY-17-(METHOXYMETHYL)-3-OXOESTRA-4,9-DIEN-11-YL]BENZALDEHYDE OXIME, ... (4 entities in total)
• Functional Keywords: progesterone receptor, pr, nuclear receptor, steroid receptor, co-repressor, asoprisnil, ncor, transcription
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 2
• Total formula weight: 32654.21

Authors

Madauss, K.P.,Deng, S.-J.,Short, S.A.,Stewart, E.L.,Williams, S.P. (deposition date: 2007-02-14, release date: 2007-03-20, Last modification date: 2023-08-30)

Primary citation

Madauss, K.P.,Grygielko, E.T.,Deng, S.J.,Sulpizio, A.C.,Stanley, T.B.,Wu, C.,Short, S.A.,Thompson, S.K.,Stewart, E.L.,Laping, N.J.,Williams, S.P.,Bray, J.D.
A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.
Mol.Endocrinol., 21:1066-1081, 2007

PubMed Abstract: Selective progesterone receptor modulators (SPRMs) have been suggested as therapeutic agents for treatment of gynecological disorders. One such SPRM, asoprisnil, was recently in clinical trials for treatment of uterine fibroids and endometriosis. We present the crystal structures of progesterone receptor (PR) ligand binding domain complexed with asoprisnil and the corepressors nuclear receptor corepressor (NCoR) and SMRT. This is the first report of steroid nuclear receptor crystal structures with ligand and corepressors. These structures show PR in a different conformation than PR complexed with progesterone (P4). We profiled asoprisnil in PR-dependent assays to understand further the PR-mediated mechanism of action. We confirmed previous findings that asoprisnil demonstrated antagonism, but not agonism, in a PR-B transfection assay and the T47D breast cancer cell alkaline phosphatase activity assay. Asoprisnil, but not RU486, weakly recruited the coactivators SRC-1 and AIB1. However, asoprisnil strongly recruited the corepressor NCoR in a manner similar to RU486. Unlike RU486, NCoR binding to asoprisnil-bound PR could be displaced with equal affinity by NCoR or TIF2 peptides. We further showed that it weakly activated T47D cell gene expression of Sgk-1 and PPL and antagonized P4-induced expression of both genes. In rat leiomyoma ELT3 cells, asoprisnil demonstrated partial P4-like inhibition of cyclooxygenase (COX) enzymatic activity and COX-2 gene expression. In the rat uterotrophic assay, asoprisnil demonstrated no P4-like ability to oppose estrogen. Our data suggest that asoprisnil differentially recruits coactivators and corepressors compared to RU486 or P4, and this specific cofactor interaction profile is apparently insufficient to oppose estrogenic activity in rat uterus.

PubMed: 17356170
DOI: 10.1210/me.2006-0524

Experimental method

X-RAY DIFFRACTION (2.6 Å)